Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
about
Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsTreatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesNew trends in molecular and cellular biomarker discovery for colorectal cancerGenomic diversity of colorectal cancer: Changing landscape and emerging targetsTreatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancerAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASColorectal cancer tumour markers and biomarkers: Recent therapeutic advancesClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerNew therapeutic strategies for BRAF mutant colorectal cancersTherapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Personalized treatment for advanced colorectal cancer: KRAS and beyondAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesAre KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Different treatment strategies and molecular features between right-sided and left-sided colon cancersReview of systemic therapies for locally advanced and metastatic rectal cancerMonoclonal antibodies for the treatment of cancerManagement of locally advanced and metastatic colon cancer in elderly patientsHow to select the optimal treatment for first line metastatic colorectal cancerIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsEpidermal growth factor receptor inhibitors: coming of ageImpact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.Role of targeted therapy in metastatic colorectal cancerMultisciplinary management of patients with liver metastasis from colorectal cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-EGFR therapy in colorectal cancerRAS and BRAF in metastatic colorectal cancer managementEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerStandard chemotherapy with cetuximab for treatment of colorectal cancerOral drugs in the treatment of metastatic colorectal cancer.Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system.Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available dataRAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Where now for anti-EGF receptor therapies in colorectal cancer?
P2860
Q26738655-605900CF-AF99-4082-8CB4-58FD04087B48Q26738801-0D452258-5E2B-413A-86C0-06E4C363FFFDQ26739049-88CFD112-1BE5-4B54-833B-B33484565755Q26739052-AF0CBD26-4EEE-4DE4-9929-53FE97C0B6A4Q26747335-2B16A93C-D2FC-457D-8AF5-25B2D538CBC1Q26748924-0590A55C-96FC-487C-9064-79D107337DC6Q26749012-6D853632-E673-4F3C-BC61-5238E5FEB5C2Q26766535-27A66310-96F3-4807-9D4F-2FEB5AACD75CQ26768427-A2926C2C-1C2B-458C-A07F-AF700443D934Q26769958-ECE5E3C8-8D47-451A-AEB2-E196EE5CD2D9Q26771952-C654B1CD-F3D3-4D17-893A-F32E51644728Q26772277-DDFB10C7-8C0D-4794-BBD5-B80E0931EC22Q26775522-286810DD-C811-439E-8863-8577237B6F1DQ26777704-C31232D2-7E0D-4269-94DA-F5D4BCB4011BQ26795558-236A7418-375F-401A-9DC7-9B0EFCE43D13Q26796348-4B1A8289-6433-4542-B4C9-B618D26F3046Q26822817-9B100B2B-3841-47E8-AF28-2DE67A2C6CE8Q26826817-80C94122-8443-4BEB-9354-BFE84F3A4EFDQ26828992-A2BA4F0F-524F-46CB-802C-929ED47DA079Q26865322-75D14CE0-FF4F-42FE-A30A-7F41B9BF9596Q27021105-C205C729-56AC-4284-B7B3-1157A33BBBCEQ27025966-CE41013E-07C5-43E3-BCA1-152F30E8F384Q27026129-6F7685AB-24DD-490E-A83C-F72B43B9555FQ27026516-8FB9789F-7DF5-4DE0-9574-9099E2F35880Q27028095-CFB52EC0-A074-4930-94EF-300D3265CFC9Q27030769-E6826435-CCAB-46EB-A890-9C91A0EA9A66Q27851892-CF31A8C7-EBD7-4A41-B68D-3E174B76BA77Q27853024-0DD4B806-8424-43F9-B2C2-5F4F2811A25CQ28068817-D0B2F9C7-FF77-43FC-BB2D-B616455B39F4Q28069575-5872ABB9-3606-4092-8030-8599BC48DD13Q28071772-83C3F0A7-6007-4288-9531-6463345DABBCQ28074073-63357119-78A0-441D-B95E-A3E87125B736Q28074175-42715254-AD86-4662-97EA-B1DC40561D1DQ28084216-E8169D58-E653-4398-AC1A-29F07383A374Q28088693-58E32F27-FC58-4C3E-A1EC-7ED4A14CC800Q30251387-31FECB1E-8545-4B71-85A4-EE4FB209B9FFQ30540615-250C57C5-F01A-44BD-867A-8967620ABBAEQ30862367-ADE68A14-A7C6-48CC-8FEB-81D356B06165Q30967175-3C208F53-555F-4249-847D-96F51CFC78A5Q31038305-4E43D626-CE7C-4B4B-839C-6FD6776B4C31
P2860
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@ast
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@en
type
label
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@ast
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@en
prefLabel
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@ast
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@en
P2093
P2860
P921
P1433
P1476
Addition of cetuximab to oxali ...... omised phase 3 MRC COIN trial.
@en
P2093
Angela M Meade
Ayman Madi
Bart Claes
Bharat Jasani
Christopher G Smith
David Fisher
Edward Kay
Jenna K Mitchell
Jeremy P Cheadle
John Bridgewater
P2860
P304
P356
10.1016/S0140-6736(11)60613-2
P407
P577
2011-06-05T00:00:00Z